DexCom Under Legal Scrutiny for Alleged Unauthorized Changes to Glucose Monitors

DexCom Under Legal Scrutiny for Alleged Unauthorized Changes to Glucose Monitors

2025-12-14 companies

New York, Saturday, 13 December 2025.
Investors must act by December 29 regarding claims DexCom secretly altered device designs, allegedly compromising reliability and posing health risks to users of its G6 and G7 systems.

Shareholders of DexCom, Inc. (NASDAQ: DXCM) are facing a critical juncture as legal scrutiny intensifies regarding the company’s continuous glucose monitoring (CGM) systems. As of today, Saturday, December 13, 2025, investors have just over two weeks to decide on their legal representation in a securities class action lawsuit that alleges significant corporate misconduct [1]. The Rosen Law Firm, a global investor rights firm, has issued a stark reminder to those who purchased DexCom securities between July 26, 2024, and September 17, 2025, emphasizing a December 29, 2025, deadline to move the Court to serve as lead plaintiff [1][3]. The core of the lawsuit rests on serious allegations that DexCom implemented unauthorized design changes to its G6 and G7 CGM systems, purportedly rendering them less reliable and exposing users to potential health risks [3].

Assessing the Financial Impact and Investor Options

The market has reacted negatively to the surrounding noise and legal challenges. As of the close of markets on December 12, 2025, DexCom stock was trading at $66.96, representing a daily decline of $1.98, or 2.87% [4]. This places the company’s market capitalization at approximately $26.12 billion [4]. The downturn is attributed in part to the volume of securities class-action notices and the uncertainty clouding the company’s product transition timeline, specifically plans to cease G6 production in 2026 [5]. While the Rosen Law Firm has set a deadline of December 29, 2025, for lead plaintiff applications, other firms such as Levi & Korsinsky and The Gross Law Firm have communicated a slightly earlier deadline of December 26, 2025, urging shareholders to act promptly [4][5].

Broader Turbulence in Diabetes Care

The legal headwinds facing DexCom are symptomatic of a broader trend of scrutiny within the diabetes management sector. Concurrently, the Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) [2]. This investigation stems from a significant market event on August 7, 2025, when Tandem’s stock plummeted 19.9% following the announcement of a voluntary medical device correction for select t:slim X2 insulin pumps [2]. The correction was issued to address a speaker-related issue that could potentially interrupt insulin delivery, mirroring the reliability concerns currently plaguing DexCom [2].

Sources


Securities Litigation Medical Devices